Oral contraceptives and hypertension in women: results of the enrollment phase of the Tabari cohort study BMC Women’s Health
Abegunde DO, Mathers CD, Adam T., Ortegon M., Strong K.: The burden and cost of chronic disease in low and middle income countries. Lancet 2007, 370 (9603): 1929-1938.
Esteghamati A., Meysamie A., Khalilzadeh O., Rashidi A., Haghazali M., Asgari F. et al. Third National Surveillance of Non-Communicable Disease Risk Factors (SuRFNCD-2007) in Iran: Methods and Findings on the Prevalence of Diabetes, Hypertension, Obesity, Central Obesity, and Dyslipidemia. BMC Public Health. 2009; 9: 167.
Simo LP, Agbor VN, Noubiap JJN et al. Hypertension Prevalence, Associated Factors, Treatment, and Control in Rural Cameroon: A Cross-Sectional Study. BMJ Open 2020; 10: e040981.
Nahimana MR, Nyandwi A., Muhimpundu MA, Olu O., Condo JU, Rusanganwa A. et al. A population-based national estimate of the prevalence and risk factors of high blood pressure in Rwanda: implications for prevention and control. BMC Public Health. 2017; 18 (1): 2.
Nascimento BR, Brant LCC, Yadgir S., Oliveira GMM, Roth G., Glenn SD, et al. Trends in prevalence, mortality and morbidity associated with high systolic blood pressure in Brazil from 1990 to 2017: Estimates from the study “Global Burden of Disease 2017” (GBD 2017). Popul Health Metr. 2020; 18 (Suppl 1): 17.
Park H, Kim K. Relationship between oral contraceptive use and the risk of high blood pressure and pre-hypertension in a cross-sectional study of Korean women. BMC Womens Health. 2013; 13:39.
Afsargharehbagh R., Rezaie-Keikhaie K., Rafiemanesh H., Balouchi A., Bouya S., Dehghan B. Hypertension and pre-hypertension in Iranian adults: a meta-analysis of prevalence, awareness, treatment, and control. Curr Hypertens Rep. 2019; 21 (4): 27.
Kheradmand M., Moosazadeh M., Saeedi M., Poustchi H., Eghtesad S., Esmaeili R. et al. Tabari cohort profile and preliminary results in urban and mountainous areas of Mazandaran, Iran. Arch Iran Med. 2019; 22 (6): 279-85.
Haghdoost AA, Sadeghirad B, Rezazadehkermani M. Epidemiology and heterogeneity of hypertension in Iran: a systematic review. Arch Iran Med. 2008; 11 (4): 444-52.
Wei W., Li Y., Chen F., Chen C., Sun T., Sun Z. et al. Dyslipidemia, combined oral contraceptives, and their interaction on the risk of hypertension in Chinese women. J Hum Hypertens. 2011; 25 (6): 364-71.
Liu H., Yao J., Wang W., Zhang D. Relationship between the duration of oral contraceptives and the risk of hypertension: a meta-analysis. J Clin Hypertens. 2017; 19: 1032-41.
Woods JW. Oral contraceptives and high blood pressure. Hypertension. 1988; 11 (3 Pt 2): II11-5.
Aghajanian A. Family Planning and Contraception in Iran, 1967â1992. Int family plan perspective. 1994; 20 (2): 66-9.
AsadiSarvestaniKh, LengKhoo S., Malina Malek N., Mat Yasin S., Ahmadi A. Comparison of the determining factors for the use of contraceptive methods between women in rural and urban areas in the Iranian district of Shiraz. Journal of Obstetrics and Reproductive Health. 2017; 5 (4): 1041-1052.
Azima S, Mousavi S. Oral contraceptive pills and high blood pressure. Int J Pharm Sci Invent. 2017; 6 (1): 47-9.
Shulman LP. The state of hormonal contraception today: the benefits and risks of hormonal contraceptives: combined contraceptives with estrogen and progestin. At J Obstet Gynecol. 2011; 205 (4): S9-S13.
Grossman D., FernÃ¡ndez L., Hopkins K., Amastae J., Potter JE. Perceptions of the safety of oral contraceptives in a predominantly Latin American population in Texas. Contraception. 2010; 81 (3): 254-60.
Barikani A, Saeedi F. Prevalence of hypertension in women over 30 years of age in Minoudar, Qazvin, Iran. ARYA Atheroscler J. 2012; 8 (special issue in the national treatment of high blood pressure): S158â62.
Sadat-Hashemi SM, Ghorbani R., Majdabadi HA, Farahani FK. Factors Related to Contraceptive Use in Tehran, Iran. Eur J Contracept Reprod Health Care. 2007; 12 (2): 148-53.
Poustchi H., Eghtesad S., Kamangar F., Etemadi A., Keshtkar AA, Hekmatdoost A. et al. Prospective Epidemiological Research Studies in Iran (PERSIAN Cohort Study): Rationale, Aims and Design. Am J Epidemiol. 2018; 187 (4): 647-55.
Eghtesad S., Mohammadi Z., Shayanrad A., Faramarzi E., Joukar F., Hamzeh B. et al. The Persian Cohort: Providing Evidence Required for Health Care Reform. Arch Iran Med. 2017; 20 (11): 691-5.
Wang C, Li Y, Bai J, Qian W, Zhou J, Sun Z, Ba L, Wei W, Li H, Sun T. General and central obesity, combined oral contraceptives, and hypertension in Chinese women. Am J Hypertens. 2011; 24 (12): 1324-30.
Farahmand M., Ramezani Tehrani F., Rostami Dovom M., Hashemi S., Azizi F. The influence of oral contraceptives on cardiometabolic parameters. J Endocrinol Invest. 2016; 39 (3): 277-83.
Chiu CL, Lind JM. Previous oral contraceptives and self-reported hypertension in postmenopausal women. BMC Public Health. 2015; 15:54.
Ribeiro CCM, Shimo AKK, Lopes MHBM, Lamas JLT. Effects of various hormonal contraceptives on blood pressure levels in women. Rev Bras Enferm. 2018; 71 (Supplement 3): 1453-1459.
Saruta T, Saade GA, Chaplain NM. A possible mechanism for oral contraceptive-induced hypertension. Decreased feedback suppression of renin release. Arch Intern Med. 1970; 126 (4): 621-6.
Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill Criteria in the 21st Century: How Data Integration Changed the Causal Inference in Molecular Epidemiology. Emerg Themes Epidemiol. 2015; 12: 14.